In an 80-patient randomized double-blind Phase 2 clinical trial evaluating Agenus' (AGEN) HerpV synthetic vaccine candidate for the treatment of genital Herpes Simplex Virus-2 (HSV-2), more than half of the 70 patients who received the vaccine developed a robust anti-HSV cytotoxic T-cell immune response. In this group of patients there was a statistically significant 75% reduction in viral load. This degree of reduction can potentially reduce the incidence and severity of herpetic outbreaks and a reduction in viral transmission.
HerpV is a recombinant therapeutic vaccine based on the company's Heat Shock Protein platform. It also contains Agenus' QS-21 Stimulon, a plant-derived adjuvant that boosts specific immune responses.
AGEN shares are up 16% premarket on moderately high volume.